Video Link: https://youtu.be/ewH2NdfOek0
In this episode, Warren Buffett and Charlie Munger were asked how do they see these two investment ideas, pharmaceuticals in ’93 and technology '01, and what difference in the two situations makes the first a good opportunity for Berkshire, and the second not one?
In this episode, you’ll learn:
What Buffett and Munger mean by pharmaceutical and tech industry are not comparable?
Why Berkshire did not invest in tech industry in 2001?
To check out all Collection: Warren Buffett <click here>
~ Please visit the site above for full video of Berkshire Hathaway Annual Meeting.
AUDIENCE MEMBER 00:00
I’d like to ask you a question which you’ve heard before, but in a slightly different context. A few years ago, you said you had made a mistake by not buying shares of the major pharmaceutical companies around 1993.
You cited their value to society, as well as their terrific growth, high profit margins, and great potential. You said that while you didn’t know which companies would do the best, you could’ve made some kind of sector play, because the entire sector had been decimated.
These exact same words, including those about not knowing which businesses will dominate over time, can also be used to describe another industry, which has recently been decimated.
This is industry is, of course, technology. How do you see these two investment ideas, pharmaceuticals in ’93 and technology now, and what difference in the two situations makes the first a good opportunity for Berkshire, and the second not one?
WARREN BUFFETT 00:49
Well, Charlie answers all the questions about mistakes, so I will turn the second question over to him. (Laughter)
CHARLIE MUNGER 01:00
Personally, I think that the future of the pharmaceutical industry was easier to predict than the future of the high-technology sector.
In the pharmaceutical sector, almost everybody did well, and some companies did extremely well. In the other sector, where there are many permanent casualties in the high-tech sector.
WARREN BUFFETT 01:33
Yeah, I would say that there’s certainly nothing obvious to us about the fact that the tech sector — as a group — viewed in aggregate — would be a good buy or be undervalued.
Whereas we should have had enough sense to recognize that the pharmaceutical industry, as a group, was undervalued.
But the pharmaceutical industry has a far, far better record of returns on large amounts of equity over time, and with a high percentage of the participants having those returns, than the tech industry. I wouldn’t regard those two as comparable at all.